Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc., which includes 1,875,000 shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares. Atea Pharmaceuticals, Inc. is listed on the Nasdaq Global Select Market under the symbol “AVIR.”

Based in Boston, Massachusetts, Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea is currently focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus, dengue virus and respiratory syncytial virus, or RSV.

The Davis Polk capital markets team included partners Richard D. Truesdell, Jr. and Yasin Keshvargar and associates Angela Park and Ariel Rivera. Partner David R. Bauer and associates Tilak Koilvaram and Jessica Brodman provided intellectual property advice. The tax team included partner Mario J. Verdolini and associate Shay Moyal. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post